Kinga Szigeti, MD
Neurology · Buffalo, NYNPI 1558461079
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,635 of the $16,734 with a category attached, or 81.5%. Biogen accounts for 71.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $10,835 and has fallen 98.1% since, to $208 in 2025.
Across 24 payments — averaging $697.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$12K
- Roche Diagnostics Corporation$3K
- Genentech, Inc.$1K
- Eisai Inc.$238
- Genentech USA, Inc.$150
- E.r. Squibb & Sons, L.L.C.$145
- plus $37 from 2 others
Across 55 payments — averaging $54,049 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.7M
- Sage Therapeutics, LLC$172K
- E.r. Squibb & Sons, L.L.C.$21K
- Genentech, Inc.$17K
- Avanir Pharmaceuticals, Inc.$16K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$10K
What the payments were for
- Consulting fees$2,41914%
- Speaking & faculty fees$13,63581%
- Travel & lodging$1451%
- Food & beverage$5353%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 10 | $11,975 |
| Roche Diagnostics Corporation | 2 | $3,124 |
| Genentech, Inc. | 1 | $1,065 |
| Eisai Inc. | 7 | $238 |
| Genentech USA, Inc. | 1 | $150 |
| E.r. Squibb & Sons, L.L.C. | 1 | $145 |
| Catalyst Pharmaceuticals, Inc. | 1 | $23 |
| GE HealthCare | 1 | $14 |
How this compares
$16,734 in reported general payments places this provider in the 80th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 103 | $22,343 |
| RexultiBrexpiprazole | 11 | $14,946 |
| Memantine Hcl | 246 | $11,603 |
| Memantine Hcl ErMemantine Hcl | 121 | $9,711 |
| Donepezil Hcl | 411 | $5,711 |
| Galantamine ErGalantamine Hbr | 12 | $1,847 |
| Risperidone | 15 | $384 |
| Escitalopram Oxalate | 38 | $309 |
| Sertraline Hcl | 29 | $248 |
| Buspirone Hcl | 30 | $205 |
| Trazodone Hcl | 30 | $196 |
Paid to pharmacies, not to this prescriber.
Other neurology in Buffalo
- Gil WolfeBuffalo$617K
- David HojnackiBuffalo$480K
- Bianca Weinstock GuttmanBuffalo$288K
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.